• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Regeneron

Regeneron antibody cocktail wins emergency use authorization

November 24, 2020 By Brian Buntz

Regeneron Pharmaceuticals (NSDQ:REGN) has announced that the FDA has granted emergency use authorization (EUA) for the combination of casirivimab and imdevimab to treat COVID-19. The monoclonal antibody cocktail is reportedly the first treatment to show “statistically significant anti-viral activity” against COVID-19, according to its developer. In a trial, the combination of drugs cut hospitalization or emergency […]

Filed Under: Biotech, Featured, Hospital Care, Pharmaceutical Tagged With: Clinical Trials, coronavirus, COVID-19, Regeneron

FDA approves first Ebola virus treatment

October 15, 2020 By Sean Whooley

The FDA granted approval to Inmazep, a mixture of three monoclonal antibodies, making it the first FDA-approved treatment for Ebola virus. Regeneron Pharmaceuticals (NSDQ:REGN) received the approval, having recently been in the news for providing its investigational COVID-19 therapeutic to President Donald Trump. Get the full story at our sister site, Drug Discovery & Development.

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance Tagged With: Ebola, FDA, Regeneron

Medtech stocks help boost S&P rally

August 18, 2020 By Sean Whooley

Medtech stocks helped the S&P 500 Index reach record highs today amid a bounceback from the lows of the COVID-19 pandemic. Reuters reported that medtech played its part in the record turn of the market, with Abiomed (NSDQ:ABMD), Regeneron Pharmaceuticals (NSDQ:REGN) and West Pharmaceutical Services (NYSE:WST), all of which are involved in developing COVID-19 therapeutics, all rising more […]

Filed Under: Business/Financial News, Featured, Wall Street Beat Tagged With: Abiomed, coronavirus, COVID-19, MedTech 100 Index, Regeneron, S&P, West Pharmaceutical Services Inc.

Mayo Clinic launches test to detect COVID-19 immunity

June 12, 2020 By Sean Whooley

Mayo Clinic announced that it launched a new SARS-CoV-2 neutralizing antibody test in support of efforts to establish therapies and vaccines for COVID-19. As part of the Expanded Access Program for Convalescent Plasma and other critical research efforts, Mayo Clinic intends to make the test available to select labs, blood banks and biopharma clients later […]

Filed Under: Business/Financial News, Diagnostics, Featured, Genomics/Molecular Diagnostics, Research & Development Tagged With: coronavirus, COVID-19, Imanis Life Sciences, Mayo Clinic, Regeneron, Vyriad

Regeneron launches clinical trial of COVID-19 antibody ‘cocktail’

June 11, 2020 By Sean Whooley

Regeneron Pharmaceuticals (NSDQ:REGN) announced today that it initiated the first clinical trial of its dual antibody cocktail for preventing COVID-19. The REGN-COV2 clinical program will include populations of hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people in groups that have a high risk of exposure (healthcare workers or first responders, for example) and uninfected people […]

Filed Under: Business/Financial News, Clinical Trials Tagged With: coronavirus, COVID-19, Regeneron

Regeneron touts one-year diabetic retinopathy data for Eylea

February 11, 2019 By Sarah Faulkner

Regeneron Pharmaceuticals (NSDQ:REGN) touted one-year results from a Phase III trial of its Eylea aflibercept injection in people with moderately severe to severe non-proliferative diabetic retinopathy. The primary endpoint of the two-year Panorama trial is the proportion of patients who experience a two-step or greater improvement in the ‘diabetic retinopathy severity scale.’ Get the full story […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: Regeneron

FDA to review Regeneron’s Eylea for diabetic retinopathy

September 13, 2018 By Sarah Faulkner

Regeneron Pharmaceuticals (NSDQ:REGN) said today that the FDA plans to review the supplemental biologics license application for Regeneron’s Eylea aflibercept injection for the treatment of diabetic retinopathy. The U.S. agency plans to make a decision about the blockbuster drug by May 13, 2019. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Regeneron

Regeneron, Sanofi strike pricing deal with Express Scripts for cholesterol drug

May 1, 2018 By Sarah Faulkner

Regeneron Pharmaceuticals (NSDQ:REGN) and its partner, Sanofi (NYSE:SNY), have agreed to lower the cost for its cholesterol drug, Praluent, for Express Scripts (NSDQ:ESRX) in exchange for an exclusive spot on the pharmacy benefit manager’s national formulary. The agreement, effective July 1, is designed to broaden patient access to the injectable medicine and lower out-of-pocket costs for eligible […]

Filed Under: Cardiovascular, Pharmaceutical, Wall Street Beat Tagged With: Express Scripts, Regeneron, Sanofi-Aventis

Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar

January 4, 2018 By Sarah Faulkner

Momenta Pharmaceuticals (NSDQ:MNTA) and Mylan (NSDQ:MYL) announced yesterday that they plan to launch a pivotal trial in the first half of 2018 for a proposed biosimilar to Regeneron‘s (NSDQ:REGN) blockbuster drug, Eylea. Eylea, a VEGF-inhibitor designed to treat wet age-related macular degeneration and diabetic macular edema, has little competition on today’s market. The drug brought in more than $5 […]

Filed Under: Clinical Trials, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: momentapharmaceuticals, Mylan, Regeneron

How this biotech plans to go up against big pharma with its eye disease products

December 29, 2017 By Sarah Faulkner

Shankar Musunuri has spent time in both the pharmaceutical world and the biotech arena – after 15 years at Pfizer (NYSE:PFE), he went on to launch several biotech start-ups. As co-founder, chairman & chief executive of Ocugen, he is looking to bring eye disease products to the patients that big pharma’s drugs have left out. “There’s so much […]

Filed Under: Biotech, Optical/Ophthalmic, Pharmaceutical, Research & Development, Wall Street Beat Tagged With: Allergan, Massachusetts Eye & Ear Infirmary, ocugen, Pfizer, Regeneron, Roche, Shire Plc.

Novartis trial results could spell trouble for Regeneron

June 21, 2017 By Sarah Faulkner

Head-to-head late-stage clinical trials published on Tuesday showed that a Novartis (NYSE:NVS) drug to treat patients with neovascular age-related macular degeneration doesn’t need to be injected as frequently as a rival drug from competitor Regeneron (NSDQ:REGN). Analysts reportedly said the data gives Novartis’ treatment, RTH258, a competitive edge compared to its rival therapies. Get the full […]

Filed Under: Clinical Trials, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: Allergan, Novartis, Regeneron, Roche

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS